ArticleClinical and molecular hepatology2026

Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B: Editorial on "Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues".

Heejoon Jang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.